Below you will find currently recruiting clinical trials for cancer patients — one click lets you show only trials conducted in Poland. The list is automatically updated from the ClinicalTrials.gov database, and we translate descriptions into Polish.
This is not medical advice — consult your oncologist
Descriptions are automatically translated with AI assistance. Always verify details in the original on ClinicalTrials.gov and consult your treating physician.
Znaleziono 2 z 1410 badań
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
It is a study of a new therapy or drug involving patients, conducted according to a strict protocol and under medical supervision. For many cancer patients, it provides access to therapies that are not yet standardly available.
Participation is free for the patient — the costs of the tested treatment are covered by the trial sponsor. Some trials also reimburse travel and accommodation costs.
Start with the trial card in our Radar — you will find eligibility criteria and contact details of the center from ClinicalTrials.gov there. Contact is usually in English; if you need support, write to us.
radar.footerNote
Alerts for new trials →